XML 12 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 22,903,253 $ 19,136,472
Short-term investments 66,755,201 85,629,412
Accounts receivable 9,864,900 15,821,511
Accounts receivable from affiliated entity 1,232,905 748,355
Prepaid expenses and other current assets 4,206,127 1,749,059
Prepaid expenses and other current assets from affiliated entity 1,816,769 1,512,424
Total current assets 106,779,155 124,597,233
Fixed assets, net 9,803,457 9,025,446
Investment in affiliated entity- GeneOne 14,443,248 16,052,065
Investment in affiliated entity - PLS 3,027,549 3,777,510
Intangible assets, net 7,222,095 7,628,394
Goodwill 10,513,371 10,513,371
Other assets 1,525,154 2,113,147
Total assets 153,314,029 173,707,166
Current liabilities:    
Accounts payable and accrued expenses 14,465,785 19,597,787
Accounts payable and accrued expenses due to affiliated entity 529,169 1,072,579
Accrued clinical trial expenses 5,909,873 6,368,389
Common stock warrants 1,051,137 1,167,614
Deferred revenue 17,060,324 14,762,720
Deferred revenue from affiliated entity 368,986 407,292
Deferred rent 617,289 446,646
Total current liabilities 40,002,563 43,823,027
Deferred revenue, net of current portion 227,481 317,808
Deferred revenue from affiliated entity, net of current portion 0 86,694
Deferred rent, net of current portion 6,963,866 5,926,424
Deferred tax liabilities 174,793 174,793
Total liabilities 47,368,703 50,328,746
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 74,627 74,062
Additional paid-in capital 563,229,335 556,718,356
Accumulated deficit (458,236,452) (434,838,235)
Accumulated other comprehensive income 781,547 1,327,968
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 105,849,057 123,282,151
Non-controlling interest 96,269 96,269
Total stockholders’ equity 105,945,326 123,378,420
Total liabilities and stockholders’ equity $ 153,314,029 $ 173,707,166